Biomodal

10 articles about Biomodal

• BIOMODAL LAUNCHES SOLUTION TO SIMULTANEOUSLY SEQUENCE GENETICS AND EPIGENETICS IN ONE WORKFLOW

  4/13/2023

  biomodal (formerly known as Cambridge Epigenetix) commercially launches its new duet multiomics solution, revealing the combinatorial power of genetic and epigenetic information from a single low volume sample.

• 

  Global Roundup: Singapore Researchers Create Atlas of Gastric Cancer

  11/4/2021

  Biopharma and life sciences organizations from across the globe provide updates on their pipelines and businesses.

• Cambridge Epigenetix announces programme for routine screening and detection of colorectal cancer and other common tumours

  1/8/2019

  Company granted broad and exclusive patent rights for the use of an epigenetic biomarker as a diagnostic tool for cancer.

• 

  Ahren Fund to Invest $10 Million in Cambridge Epigenetix

  9/4/2018

  Eight so-called “superstar scientists” based in Cambridge, UK, have co-founded an investment fund dubbed Ahren with 100 million pounds, so far. One of their first investments is in biotech company Cambridge Epigenetix for $10 million.

• Cambridge Epigenetix Appoints Professor Mark Dawson as Scientific Advisor

  11/27/2017

  The appointment further strengthens CEGX's panel of opinion leaders providing expert advice across the Company's key focus areas of epigenetics, oncology, liquid biopsy, diagnostic and therapeutic development.

• Cambridge Epigenetix And NuGEN Sign Partnership Agreement To Combine Leading Technologies In Epigenetics Research

  8/15/2017

• Cambridge Epigenetix Licenses Fundamental DNA Methylation IP From Boston Children’s Hospital

  4/28/2017

• Cambridge Epigenetix Establishes Scientific Advisory Board

  3/6/2017

• Cambridge Epigenetix Introduces TrueMethyl Whole Genome Integrated Workflow For Epigenetic Analysis

  10/18/2016

• Startup Cambridge Epigenetix Nabs $21 Million and Plucks New CEO from Illumina

  3/15/2016